Document:

Exhibit 4.1

 

NEITHER THE SECURITIES EVIDENCED BY THIS
CERTIFICATE NOR THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS SECURITY HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THE SECURITIES MAY NOT
BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT (1) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OR (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE
STATE SECURITIES LAWS AND THE SECURITIES LAWS OF OTHER JURISDICTIONS, AND IN THE CASE OF A TRANSACTION EXEMPT FROM REGISTRATION,
UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION
UNDER THE SECURITIES ACT AND SUCH OTHER APPLICABLE LAWS.

 

COMMON STOCK PURCHASE WARRANT

 

 

Rezolute,
Inc.

 

	Warrant Shares: _______1/	Issue Date: October 9, 2020
	 	 
	 	Initial Exercise Date: October 9, 2020

 

THIS COMMON STOCK PURCHASE
WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City
time) on October 9, 2027 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Rezolute,
Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant
Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”). The purchase
price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

 

Section 1.              Definitions.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the “Purchase Agreement”), dated October 8, 2020, among the Company and the purchasers signatory thereto.

 

 

 

1/ Insert
number of Warrant Shares equal to 33% of the number of Unit Shares subscribed for by such holder, rounded up or down to the nearest
whole number.

 

    1

     

    

 

Section 2.            Exercise.

 

a)                 
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part,
at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of
a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed
hereto as Exhibit A (the “Notice of Exercise”). Within the earlier of (i) two (2) trading days and (ii) the
number of trading days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise
as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of
Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified
in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the
Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the
Holder shall surrender this Warrant to the Company for cancellation within three (3) trading days of the date on which the final
Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total
number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records
showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice
of Exercise within one (1) trading day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares
hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.

 

b)                 
Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $0.39, subject to
adjustment hereunder (the “Exercise Price”).

 

c)                 
Cashless Exercise. This Warrant may also be exercised, in whole or in part, at such time by means of a “cashless
exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing
[(A-B) times (X)] by (A), where:

 

(A)
= as applicable: (i) the VWAP on the trading day immediately preceding the date of the applicable Notice of Exercise if such Notice
of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a trading day or (2) both
executed and delivered pursuant to Section 2(a) hereof on a trading day prior to the opening of “regular trading hours”
(as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such trading day, (ii) at the
option of the Holder, either (y) the VWAP on the trading day immediately preceding the date of the applicable Notice of Exercise
or (z) the Bid Price of the Common Stock on the principal trading market as reported by Bloomberg L.P. as of the time of the Holder’s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours”
on a trading day and is delivered within [two (2) hours] thereafter (including until [two (2) hours] after the close of “regular
trading hours” on a trading day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice
of Exercise if the date of such Notice of Exercise is a trading day and such Notice of Exercise is both executed and delivered
pursuant to Section 2(a) hereof after the close of “regular trading hours” on such trading day;

 

    2

     

    

 

(B) = the
Exercise Price of this Warrant, as adjusted hereunder; and

 

(X) =
the number of Warrant Shares, as adjusted hereunder, that would be issuable upon the applicable exercise of this Warrant in accordance
with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

 

“Bid
Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common
Stock is then listed or quoted on a trading market, the bid price of the Common Stock for the time in question (or the nearest
preceding date) on the trading market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on
a trading day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is then listed or
quoted on OTCQB or OTCQX and OTCQB or OTCQX, as applicable, is not a trading market, the volume weighted average price of the Common
Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on a trading market or, if applicable, OTCQB or OTCQX, and if prices for the Common Stock are then reported
on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent
bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock
as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then
outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

“VWAP” means,
for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a trading market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the trading market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a trading day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)  the
Common Stock is then listed or quoted on OTCQB or OTCQX and if OTCQB or OTCQX, as applicable is not a trading market,
the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as
applicable, (c) if the Common Stock is not then listed or quoted for trading on a trading market or, if applicable, OTCQB or
OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency
succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or
(d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable
to the Company, the fees and expenses of which shall be paid by the Company.

 

    3

     

    

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period
of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.  The Company agrees not to
take any position contrary to this Section 2(c).

 

Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).

 

d)                 
Mechanics of Exercise.

 

i.            Delivery
of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the
Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The
Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is
then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the
Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the
Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and
otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder
or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address
specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) trading days after the
delivery to the Company of the Notice of Exercise, (ii) one (1) trading day after delivery of the aggregate Exercise Price to
the Company and (iii) the number of trading days comprising the Standard Settlement Period after the delivery to the Company
of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of
Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided
that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share
Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of
Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a
penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the
applicable Notice of Exercise), $10 per trading day (increasing to $20 per trading day on the fifth trading day after such
liquidated damages begin to accrue) for each trading day after such Warrant Share Delivery Date until such Warrant Shares are
delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST
program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement
Period” means the standard settlement period, expressed in a number of trading days, on the Company’s primary
trading market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.

 

    4

     

    

 

ii.           
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at
the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver
to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant,
which new Warrant shall in all other respects be identical with this Warrant.

 

iii.           
Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares
on a timely basis pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind
such exercise.

 

iv.            Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the
Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the
provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such
date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s
brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant
Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A)
pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage
commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the
number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue
times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of
the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was
not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common
Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For
example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an
attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000,
under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder
shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon
request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any
other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise
of the Warrant as required pursuant to the terms hereof.

 

    5

     

    

 

v.           
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon
the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such
exercise, the Company shall, round up to the next whole share.

 

vi.           
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue
or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses
shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may
be directed by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other
than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto
as Exhibit B, duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient
to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing
of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing
similar functions) required for same-day electronic delivery of the Warrant Shares.

 

vii.           
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely
exercise of this Warrant, pursuant to the terms hereof.

 

    6

     

    

 

e)                  Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such
Persons, “Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation
(as defined below).  For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by
the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon
exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of
Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially
owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock
Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially
owned by the Holder or any of its Affiliates or Attribution Parties.  Except as set forth in the preceding sentence, for
purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not
representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is
solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation
contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be
the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case
subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of
such determination. In addition, a determination as to any group status as contemplated above shall be determined in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this
Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the
Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.  Upon the written or
oral request of a Holder, the Company shall within one (1) trading day confirm orally and in writing to the Holder the number
of shares of Common Stock then outstanding.  In any case, the number of outstanding shares of Common Stock shall be
determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the
Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock
was reported. The “Beneficial Ownership Limitation” shall be [4.99/9.99%] of the number of shares of the
Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of
this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions
of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of
the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this
Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial
Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The
provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the
terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the
intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to
properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of
this Warrant.

 

    7

     

    

 

Section 3.                    Certain
Adjustments.

 

a)                 
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend
or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a)
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

b)                  Subsequent
Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to
the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be
entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could
have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant
(without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no
such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant,
issue or sale of such Purchase Rights (provided, however, that to the extent that the Holder’s right to
participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the
Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in
abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the
Beneficial Ownership Limitation).

 

    8

     

    

 

c)                 
Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or
make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock,
by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities,
property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other
similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such
case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated
therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that
to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial
ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the
Holder exceeding the Beneficial Ownership Limitation).

 

    9

     

    

 

d)                  Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more
related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (and
all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer,
conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii)
any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is
completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other
securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the
Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or
recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or
more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of
Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including
any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the
other Persons making or party to, such stock or share purchase agreement or other business combination) (each a
 “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the
right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence
of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the
exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company,
if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this
Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on
the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be
appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in
respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price
among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the
Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be
received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it
receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary,
in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the
Holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the
Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction),
purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined
below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction;
provided, however, that, if the Fundamental Transaction is not within the Company's control, including not approved by the
Company's Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type
or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant,
that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction,
whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock
are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction;
provided, further, that, if holders of Common Stock of the Company are not offered or paid any consideration in such
Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity
(which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. “Black
Scholes Value” means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the
 “OV” function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for
pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to
the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B)
an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg
(determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of
the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of
(i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being
offered in such Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public
announcement of such Fundamental Transaction and (y) the last VWAP immediately prior to the consummation of such Fundamental
Transaction and (D) a remaining option time equal to the time between the date of the public announcement of the applicable
Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will
be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business
Days of the Holder’s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause
any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor
Entity”) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction
Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance
reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the
Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is
exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent
to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on
the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise
price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital
stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the
consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon
the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that
from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents
referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power
of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents
with the same effect as if such Successor Entity had been named as the Company herein.

 

    10

     

    

 

e)                 
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a
share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding
as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

f)                  
Notice to Holder.

 

i.            Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall
promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any
resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such
adjustment.

 

ii.           
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase
any shares of capital stock of any class or of any rights, (D) the approval of stockholders of the Company shall be required in
connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale
or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock
is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile
or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company,
at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the record
date for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date
as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is
expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall
be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein
or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the
extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company
or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report
on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice
to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

g)                  Voluntary
Adjustment By Company. Subject to the rules and regulations of the trading market upon which the Common Stock may be
listed, the Company may at any time during the term of this Warrant, subject to the prior written consent of the Holder,
reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors
of the Company.

 

    11

     

    

 

Section 4.                     Transfer
of Warrant.

 

a)                 
Transferability. Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder
(including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant
at the principal office of the Company or its designated agent, together with a guaranteed written assignment of this Warrant substantially
in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes
payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver
a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified
in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned,
and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder
shall surrender this Warrant to the Company within three trading days of the date on which the Holder delivers an assignment form
to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a
new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

b)                 
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid
office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
thereto.

 

c)                 
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

d)                  Transfer
Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the
transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the
Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or
manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a
condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the
provisions of the Purchase Agreement.

 

    12

     

    

 

e)                 
Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring
this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and
not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act
or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.

 

Section 5.                      Miscellaneous.

 

a)                 
No Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting
rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i),
except as expressly set forth in Section 3. Without limiting the rights of a Holder to receive Warrant Shares on a “cashless
exercise,” and to receive the cash payments contemplated pursuant to Sections 2(d)(i) and 2(d)(iv), in no event will the
Company be required to net cash settle an exercise of this Warrant.

 

b)                 
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to
the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in
the case of the Warrant, shall include the posting of a bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

c)                 
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of
any right required or granted herein shall not be a trading day, then, such action may be taken or such right may be exercised
on the next succeeding trading day.

 

d)                 
Authorized Shares.

 

The Company
covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under
this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers
who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this
Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be
issued as provided herein without violation of any applicable law or regulation, or of any requirements of the trading market
upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the
exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this
Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and
nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than
taxes in respect of any transfer occurring contemporaneously with such issue).

 

    13

     

    

 

Except and
to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be necessary to enable the Company to perform its obligations under this Warrant.

 

Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.

 

e)                 
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant
shall be determined in accordance with the provisions of the Purchase Agreement.

 

f)                  
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not
registered pursuant to that certain Registration Rights Agreement dated October 8, 2020, among the Company and the purchasers signatory
thereto, will have restrictions upon resale imposed by state and federal securities laws.

 

g)                  Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding the
fact that the right to exercise this Warrant terminates on the Termination Date. Without limiting any other provision of this
Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient
to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate
proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its
rights, powers or remedies hereunder.

 

    14

     

    

 

h)                 
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the
Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.

 

i)                  
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise
this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to
any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability
is asserted by the Company or by creditors of the Company.

 

j)                  
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of
damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)                 
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced
hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors
and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time
of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

 

l)                  
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the
Company, on the one hand, and the Holder of this Warrant, on the other hand.

 

m)              
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)                 
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose,
be deemed a part of this Warrant.

 

********************

 

(Signature Page Follows)

 

    15

     

    

 

 

IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

		Rezolute, Inc.
	 	 
	 	By:	 
	 	 	Name: Keith Vendola
	 	 	Title: Chief Financial Officer

 

    16

     

    

 

EXHIBIT A

NOTICE OF EXERCISE

 

To:       Rezolute,
Inc.

 

(1)  
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.

 

(2)  
Payment shall take the form of (check applicable box):

 

 ̈
in lawful money of the United States; or

 

 ̈
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the
cashless exercise procedure set forth in subsection 2(c).

 

(3)  
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

 

The Warrant Shares shall be delivered to
the following DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4)  
The time of day this Notice of Exercise is being executed is:

 

 

_______________________________

 

(5)  
Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated
under the Securities Act of 1933, as amended.

 

 

[SIGNATURE
OF HOLDER]

 

	Name of Investing Entity:	 

	Signature of Authorized Signatory of Investing Entity:	 

	Name of Authorized Signatory:	 

	Title of Authorized Signatory:	 

	Date:	 

 

     

     

    

 

EXHIBIT B

 

 

ASSIGNMENT
FORM

(To assign the
foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase
shares.)

 

FOR VALUE RECEIVED,
the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name: 	 
	 	(Please Print)

 

	Address: 	 
	 	(Please Print)

 

	Phone Number:	 
	 	 
	Email Address:	 

 

	Dated:	_________________, ______

 

	Holder’s Signature:	                                                                                                      

 

	Holder’s Printed Name:	                                                                                                                       

 

	Holder’s Address:Exhibit 10.1

 

SECURITIES
PURCHASE AGREEMENT

 

THIS SECURITIES PURCHASE
AGREEMENT (this “Agreement”) is made as of October 8, 2020 by and among Rezolute, Inc., a Delaware corporation
(the “Company”), and each of those persons and entities, severally and not jointly, identified as an Investor
on the Schedule of Investors attached as Exhibit A hereto (the “Schedule of Investors”). Such persons
and entities together with their permitted successors and assigns, are referred to collectively as the “Investors”
and each individually as an “Investor”. The Company and the Investors may each be referred to herein individually
as a “Party” and collectively as the “Parties.”

 

RECITALS

 

A.       The
Parties are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section
4(a)(2) of the Securities Act and the provisions of Regulation D (“Regulation D”) or other applicable exemptions
from registration, as promulgated by the U.S. Securities and Exchange Commission (the “SEC”) under the Securities
Act.

 

B.       The
Investors wish to purchase, severally but not jointly, from the Company, and the Company wishes to sell and issue to the Investors,
upon the terms and conditions stated in this Agreement, units (“Units”) having an aggregate purchase price
of $0.33, each such Unit consisting of (i) one (1) share of the Company’s common stock, par value $0.001 per share (the
 “Common Stock”), and (ii) a warrant to purchase 0.33 shares of Common Stock (the “Warrants”);
provided that, for the avoidance ‎of doubt, all share numbers and prices referenced in this Agreement are before the
reverse stock split referred to in Section 7 hereof (the “Reverse Stock Split”).

 

C.       Contemporaneously
with the execution and delivery of this Agreement, the Parties will execute and deliver a Registration Rights Agreement, in the
form attached hereto as Exhibit A (the “Registration Rights Agreement”), pursuant to which the Company
agrees to provide certain registration rights with respect to the Shares and the Warrant Shares under the Securities Act and applicable
state securities Laws.

 

D.       The
Company has engaged Canaccord Genuity LLC and JMP Securities LLC as its exclusive placement agents (the “Placement Agents”)
and has engaged Griffin Securities, Inc. (the “Advisor”) for the offering of the Units on a “best efforts”
basis.

 

In consideration of
the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties agree as follows:

 

1.            
Definitions. In addition to those terms defined elsewhere in this Agreement, for the purposes of this Agreement,
the following terms shall have the meanings set forth below:

 

“Affiliate”
means, with respect to any Person, any other Person which directly or indirectly through one or more intermediaries Controls, is
controlled by, or is under common Control with, such Person.

 

    1

     

    

 

“Business Day”
means any day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business.

 

“Closing Date”
means the Trading Day when all of the Transaction Documents have been executed and delivered by the applicable parties thereto,
and all of the conditions set forth in Section 6.1 and Section 6.2 hereof are satisfied or waived by the Required
Investors, as the case may be, or such other date as the Company and the Required Investors may agree.

 

“Company Counsel”
means Dorsey & Whitney LLP, with offices located at 1400 Wewatta Street, Suite 400, Denver, CO 80202-5549.

 

“Company Intellectual
Property Counsel” means Kilpatrick Townsend & Stockton LLP, with offices located at 1400 Wewatta Street, Suite 600,
Denver, CO 80202-5549.

 

“Company’s
Knowledge” means with respect to any statement made to the knowledge of the Company, that the statement is based upon
the actual knowledge of (i) the directors of the Company, or (ii) the officers (as such term is defined in Rule 405 under the Exchange
Act) of the Company who, as of the date hereof, have responsibility for the matter or matters that are the subject of the statement,
and the knowledge that each such person would reasonably be expected to have after reasonable inquiry with respect to the matters
in question.

 

“Contract”
means any written agreement, contract, subcontract, lease, understanding, arrangement, instrument, note, option, warranty, purchase
order, license, sublicense, insurance policy, benefit plan or legally binding commitment or undertaking of any nature.

 

“Control”
(including the terms “controlling,” “controlled by” or “under common control with”) means the
possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether
through the ownership of voting securities, by contract or otherwise.

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

 

“Exempt Issuance”
means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant to any
stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the board of directors or a majority
of the members of a committee of non-employee directors established for such purpose for services rendered to the Company or (b)
securities upon the exercise or exchange of or conversion of any securities issued hereunder and/or other securities exercisable
or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that
such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations)
or to extend the term of such securities.

 

    2

     

    

 

“Insider”
means each director, executive officer, other officer of the Company participating in the offering, any beneficial owner of twenty
percent (20%) or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, and
any promoter connected with the Company in any capacity on the Effective Date.

 

“Law”
or “Laws” means any federal, state, local, municipal, foreign or other law, statute, constitution, principle
of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated,
implemented or otherwise put into effect by or under the authority of any governmental authority.

 

“Lead Investor”
means CAM Capital LLC and/or its Affiliates.

 

“Material Adverse
Effect” means a material adverse effect on the (i) validity or enforceability of or the Company’s ability to perform
in any material respect its obligations under this Agreement or (ii) earnings, results of operations, assets, properties, prospects,
business or condition (financial or otherwise) of the Company and its subsidiaries, taken as a whole, except that any of the following,
either alone or in combination, shall not be deemed a Material Adverse Effect: (i) effects caused by changes or circumstances
affecting general market conditions in the U.S. or applicable foreign economy or effects generally applicable to the industry in
which the Company operates, (ii) effects resulting from or relating to the announcement or disclosure of the sale of the Securities
or other transactions contemplated by this Agreement, (iii) effects caused by any event, occurrence or condition resulting
from or relating to the taking of any action in accordance with this Agreement, (iv) changes in the trading price or trading volume
of the Company’s Common Stock (but not the underlying causes thereof), (v) the filing of any stockholder or derivative litigation
arising from or relating to the execution of this Agreement or the consummation of the transactions contemplated hereby, or (vi)
effects caused by earthquakes, global pandemics, hostilities, acts of war, sabotage or terrorism or military actions or any escalation
or material worsening of any such global pandemics, hostilities, acts of war, sabotage or terrorism or military actions existing
as of the date hereof, except, with respect to clauses (i) and (vi), to the extent that the effects of such changes or events are
disproportionately adverse to the earnings, results of operations, assets, properties, prospects, business or condition (financial
or otherwise) of the Company and its subsidiaries, taken as a whole.

 

“Order”
means any order, writ, injunction, judgment or decree.

 

“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company,
joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein.

 

“Preemptive
Period” means so long as the Lead Investor holds at least 50% of the shares of Common Stock purchased by the Lead Investor
on the date hereof under the Agreement, as adjusted for the Reverse Stock Split (it being understood that any subsequent issuance
by the Company of additional shares resulting in the dilution of the Lead Investor’s ownership of the Company shall not impair
Lead Investor’s rights hereunder).

 

“Purchase Price”
means $0.33 per Unit.

 

    3

     

    

 

“Qualified Percentage
Interest” means, as of any date of determination, the percentage equal to (i) the number of shares of Common Stock (on
an as-converted basis) then held by the Lead Investor as of the date of determination, divided by (ii) the total number of outstanding
shares of Common Stock (on an as-converted basis) as of such date.

 

“Registration
Statement” has the meaning set forth in the Registration Rights Agreement.

 

“Required Investors”
means the Investors beneficially owning (calculated in accordance with Rule 13d-3 under the Exchange Act) a majority of the aggregate
outstanding Shares.

 

“Securities”
means the Units, the Shares, the Warrants and the Warrant Shares.

 

“Securities
Act” means the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated
thereunder.

 

“Shares”
means the aggregate number of shares of Common Stock being purchased by the Investors hereunder.

 

“Subscription
Amount” means, with respect to each Investor, the aggregate amount to be paid for the Units purchased by such Investor
hereunder as indicated on such Investor’s signature page hereto next to the heading “Aggregate Purchase Price (Subscription
Amount)” in United States dollars.

 

“Subsidiary”
of any Person means another Person, an amount of the voting securities, other voting ownership or voting partnership interests
of which is sufficient to elect at least a majority of its Board of Directors or other governing body (or, if there are no such
voting interests, fifty percent (50%) or more of the equity interests of which) is owned directly or indirectly by such first Person.

 

“Transaction
Documents” means this Agreement, the Warrants and the Registration Rights Agreement.

 

“Warrant Shares”
means the shares of Common Stock issuable upon exercise of or otherwise pursuant to the Warrants.

 

2.                 
Purchase and Sale of the Units. Subject to the terms and conditions of this Agreement, at the Closing, each Investor
shall severally, and not jointly, purchase, and the Company shall sell and issue to such Investor, such number of Units equal to
the quotient resulting from dividing (i) the Subscription Amount for such Investor by (ii) the Purchase Price, rounded
down to the nearest whole Share. The number of Warrant Shares contained in the Units shall be rounded up or down to the nearest
whole number. The Warrants shall have an exercise price equal to $0.39 per Warrant Share (subject to adjustment as provided in
such Warrants).

 

3.                
Closing. The closing of the issuance and sale of the Units (the “Closing”) shall occur remotely
via the exchange of documents and signatures on the Closing Date. At the Closing, each Investor shall deliver or cause to be delivered
to the Company the Subscription Amount for such Investor (against, and concurrently with, delivery of the Shares and Warrants to
such Investor), via wire transfer of immediately available funds pursuant to the wire instructions delivered to such Investor by
the Company prior to the Closing. At the Closing, the Company shall (i) instruct the transfer agent for the Common Stock (the “Transfer
Agent”) to credit each Investor the number of Shares set forth on such Investor’s signature page hereto (and, upon
request of such Investor, shall instruct the Transfer Agent to deliver stock certificates to such Investor representing such Shares)
and (ii) deliver to each Investor a Warrant, executed by the Company and registered in the name of such Investor, exercisable
for the number of Warrant Shares as indicated on such Investor’s signature page hereto next to the heading “Underlying
Shares Subject to Warrant”. Immediately after the Closing, the Company or the Transfer Agent will deliver to each Purchaser
evidence of the issuance to such Purchaser of the Shares on and as of the Closing Date.

 

    4

     

    

 

4.             
Representations and Warranties of the Company. The Company hereby represents and warrants to the Investors, the Placement
Agents and the Advisor that, except as set forth in the schedules delivered herewith or as disclosed in the SEC Filings (as defined
below), as of the date hereof and as of the Closing Date as follows:

 

4.1             
Organization, Good Standing and Qualification. Each of the Company and its Subsidiaries is a corporation duly organized,
validly existing and in good standing under the Laws of the jurisdiction of its incorporation and has all requisite corporate power
and authority to carry on its business as now conducted and to own its assets. Each of the Company and its Subsidiaries is duly
qualified to do business as a foreign corporation and is in good standing in each jurisdiction in which the nature of its business
makes such qualification necessary unless the failure to so qualify or be in good standing would not reasonably be expected to
have a Material Adverse Effect.

 

4.2             
Authorization. The Company has all requisite corporate power and authority and has taken all requisite action on
the part of the Company, its officers, directors and stockholders necessary for (i) the authorization, execution and delivery of
the Transaction Documents, (ii) the authorization of the performance of all obligations of the Company hereunder or thereunder,
including the Reverse Stock Split and Nasdaq stock listing referenced in Section 4.27 and Section 7.2, and (iii)
the authorization, issuance (or reservation for issuance) and delivery of the Securities. The Transaction Documents constitute
the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject
to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar Laws of general applicability, relating
to or affecting creditors’ rights generally and to general equitable principles.

 

4.3             
Capitalization.

 

(a)              
The authorized capital stock of the Company consists of (i) 500,000,000 shares of Common Stock, of which 293,320,891 shares
are issued and outstanding as of the date hereof, and (ii) 20,000,000 shares of preferred stock, par value $0.001 per share, of
which no shares are outstanding as of the date hereof. No shares of capital stock are held in Company’s treasury. All outstanding
shares of Common Stock are duly authorized, validly issued, fully paid and non-assessable and were issued in compliance with all
applicable federal and state securities Laws.

 

    5

     

    

 

(b)              
As of the date hereof, the Company had reserved an aggregate of 49,940,417 shares of Common Stock, net of exercises, for
issuance to employees, consultants and non-employee directors pursuant to the Company’s Equity Incentive Plan, under which
options were outstanding for an aggregate of 47,222,917 shares of Common Stock. In addition, as of the date hereof the Company
had reserved an aggregate of 30,914,992 shares of Common Stock, net of exercises, for issuance to former investors and financial
advisors, pursuant to outstanding warrant agreements. All shares of Common Stock subject to issuance as aforesaid, upon issuance
on the terms and conditions specified in the instruments pursuant to which they are issuable, would be duly authorized, validly
issued, fully paid and non-assessable.

 

(c)              
Except as set forth in subsection 4.3(b), there are no: (i) outstanding subscriptions, options, calls, warrants or rights
(whether or not currently exercisable) to acquire any shares of the capital stock or other securities of the Company or any Subsidiary
thereof; (ii) outstanding securities, instruments or obligations that are or may become convertible into or exchangeable for any
shares of the capital stock or other securities of the Company or any Subsidiary thereof; (iii) stockholder rights plans (or similar
plans commonly referred to as a “poison pill”) or Contract under which the Company or any Subsidiary thereof are or
may become obligated to sell or otherwise issue any shares of its capital stock or any other securities; or (iv) conditions or
circumstances that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person
is entitled to acquire or receive any shares of capital stock or other securities of the Company or any Subsidiary thereof. Except
as set forth in subsection 4.3(b), there are no outstanding or authorized stock appreciation, phantom stock, profit participation,
restricted stock units, equity-based awards or other similar rights with respect to the Company or any Subsidiary thereof.

 

(d)              
(i) none of the outstanding shares of Common Stock are entitled or subject to any preemptive right, right of repurchase
or forfeiture, right of participation, right of maintenance or any similar right; (ii) none of the outstanding shares of Common
Stock are subject to any right of first refusal in favor of the Company; (iii) there are no outstanding bonds, debentures, notes
or other indebtedness of the Company or any Subsidiary thereof having a right to vote on any matters on which the stockholders
of Company have a right to vote; and (iv) there is no Contract to which the Company or any Subsidiary thereof is a party relating
to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or from
granting any option or similar right with respect to), any shares of Common Stock (other than the Registration Rights Agreement
and this Agreement). Neither the Company nor any Subsidiary thereof is under any obligation, or is bound by any Contract pursuant
to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Common Stock or other securities.

 

4.4             
Valid Issuance. The Shares have been duly and validly authorized and, when issued and paid for pursuant to this Agreement,
will be validly issued, fully paid and nonassessable, and shall be free and clear of all encumbrances and restrictions (other than
those created by the Investors), except for restrictions on transfer imposed by applicable securities Laws. The Warrants have been
duly authorized and, when issued and paid for in accordance with the terms of the Transaction Documents, will be duly and validly
issued, and shall be free and clear of all encumbrances and restrictions (other than those created by the Investors), except for
restrictions on transfer imposed by applicable securities Laws. The Warrant Shares issuable upon exercise of the Warrants have
been duly authorized and, when issued and paid for in accordance with the terms of the Warrants, will be duly and validly issued,
fully paid and nonassessable, and shall be free and clear of all encumbrances and restrictions (other than those created by the
Investors), except for restrictions on transfer imposed by applicable securities Laws.

 

    6

     

    

 

4.5             
Consents. The execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance
and sale of the Securities require no consent of, action by or in respect of, or filing with, any governmental authority other
than those that have been made or obtained as of the date hereof and post-sale filings pursuant to securities Laws and the rules
and regulations of the Nasdaq Capital Market (the “Nasdaq Capital Market”), which the Company undertakes to
file within the applicable time periods.

 

4.6             
SEC Filings.

 

(a)              
The Company has filed all reports, schedules, forms, statements and other documents required to be filed by it under the
Exchange Act for the three (3)-year period preceding the Effective Date (or such shorter period as the Company was required by
Law to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein,
being collectively referred to herein as the “SEC Filings”).

 

(b)              
At the time of filing thereof, or to the extent corrected by a subsequent filing, the SEC Filings complied as to form in
all material respects with all applicable requirements of the Exchange Act and did not contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein,
in the light of the circumstances under which they were made, not misleading.

 

(c)              
Each registration statement and any amendment thereto filed by the Company during the three (3) year period preceding the
date hereof pursuant to the Securities Act, as of the date such statement or amendment became effective, complied as to form in
all material respects with the Securities Act and did not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the statements made therein not misleading; and each
prospectus filed during the three (3) year period preceding the date hereof pursuant to Rule 424(b) under the Securities Act, as
of its issue date and as of the closing of any sale of securities pursuant thereto, did not contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein,
in the light of the circumstances under which they were made, not misleading.

 

4.7             
No Material Adverse Change. Since March 31, 2020, as identified and described in the SEC Filings, there has not been
(i) any change in the consolidated assets, liabilities, financial condition or operating results of the Company or its Subsidiaries
from that reflected in the financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended
March 31, 2020, except for changes in the ordinary course of business that have not had a Material Adverse Effect, or
(ii) any event or condition that has had a Material Adverse Effect.

 

    7

     

    

 

4.8             
No Conflict, Breach, Violation or Default. The execution, delivery and performance of the Transaction Documents by
the Company and the issuance and sale of the Securities will not (i) conflict with or result in a material breach or material violation
of (a) any of the terms and provisions of, or constitute a default under, the Company’s Certificate of Incorporation or the
Company’s Bylaws, both as in effect as of immediately prior to the Closing, or (b) any Law or Order of any governmental authority
(including any court, domestic or foreign), in each case having jurisdiction over the Company, any Subsidiary thereof or any of
their respective assets or properties, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of
time or both would become a default) under, result in the creation of any lien, encumbrance or other adverse claim upon any of
the properties or assets of the Company or any Subsidiary thereof or give to others any rights of termination, amendment, acceleration
or cancellation (with or without notice, lapse of time or both) of, any Contract; except in the case of clauses (i)(b) and (ii)
such as would not have a Material Adverse Effect.

 

4.9             
Tax Matters. The Company and each of its Subsidiaries has timely filed all material tax returns required to have
been filed by the Company or such Subsidiary with all appropriate governmental authorities. All such tax returns were correct and
complete in all material respects and have been prepared in material compliance with all applicable Laws. The Company and each
Subsidiary thereof have paid all material taxes due and owing on or before the Effective Date, except those being contested in
good faith with respect to which adequate reserves have been reserved for on the books of the Company.

 

4.10         
Transfer Taxes. There are no transfer taxes or other similar fees or charges under Federal law or the laws of any
state, or any political subdivision thereof, required to be paid in connection with the execution and delivery of this Agreement
or the issuance by the Company or sale by the Company of the Securities.

 

4.11         
Litigation. There is no claim, action, suit, arbitration or similar proceeding pending against or affecting or, to
the Company’s Knowledge, threatened against the Company, its Subsidiaries or any of its or their properties or, to the Company’s
Knowledge, any director or officer of the Company (in his or her capacity as such), in each case that would have a Material Adverse
Effect.

 

4.12         
Financial Statements. The financial statements of the Company contained or incorporated by reference in each SEC
Filing: (i) complied as to form in all material respects with the rules and regulations of the SEC with respect thereto as in effect
at the time of filing (or to the extent corrected by a subsequent restatement); (ii) present fairly, in all material respects,
the consolidated financial position of the Company and its Subsidiaries as of the dates presented and the results of operations
and cash flows for the periods presented; and (iii) were prepared in conformity with United States generally accepted accounting
principles applied on a consistent basis (except as may be indicated in the notes to such financial statements or, in the case
of unaudited financial statements, as permitted by Form 10-Q of the SEC, and except that the unaudited financial statements may
not contain footnotes and are subject to normal and recurring year-end adjustments).

 

    8

     

    

 

4.13         
Intellectual Property. The Company and each of its Subsidiaries owns, possesses, licenses or has other rights to
use, or can obtain on commercially reasonable terms, all patents, patent applications, trade and service marks, trade and service
mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology, know-how and other intellectual property
(collectively, the “Intellectual Property”) used in the conduct of the Company’s and each of its Subsidiaries’
businesses as now conducted or as proposed in the SEC Filings to be conducted (the “Company Intellectual Property”).
To the Knowledge of the Company, there are no rights of third parties to any owned Company Intellectual Property, other than as
licensed by the Company. To the Knowledge of the Company, there is no infringement by third parties of any owned Company Intellectual
Property. There is no pending or, to the Company’s Knowledge, threatened action, suit, proceeding or claim by others challenging
the Company’s rights in or to any Company Intellectual Property. There is no pending or, to the Company’s Knowledge,
threatened action, suit, proceeding or claim by others challenging the validity or scope of any owned Company Intellectual Property.
There is no pending or, to the Company’s Knowledge, threatened action, suit, proceeding or claim by others that the Company
infringes or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights of others. To the Company’s
Knowledge, there are no material facts required to be disclosed to the U.S. Patent and Trademark Office (“USPTO”)
which have not been disclosed to the USPTO and which would preclude the grant of a patent in connection with any patent application
of the Company Intellectual Property or could form the basis of a finding of invalidity with respect to any issued patents of the
Company Intellectual Property.

 

4.14         
Disclosure. The Company understands and confirms that the Investors will rely on the foregoing representations in
effecting transactions in securities of the Company. To the Knowledge of the Company, all due diligence materials regarding the
Company, its Subsidiaries, their businesses and the transactions contemplated hereby, furnished by or on behalf of the Company
or its Subsidiaries to the Investors upon their request are, when taken together with the SEC Filings, true and correct in all
material respects and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order
to make the statements made therein, in light of the circumstances under which they were made, not misleading.

 

4.15         
Contracts. Each franchise, contract or other document of a character required to be described in the SEC Filings
or to be filed as an exhibit to the SEC Filings under the Securities Act and the rules and regulations promulgated thereunder (collectively,
the “Material Contracts”) is so described or filed.

 

4.16         
Compliance. Except as would not, individually or in the aggregate, result in a Material Adverse Effect: (i) the Company
and each of its Subsidiaries are and have been for the three (3)-year period preceding the date hereof in compliance with statutes,
laws, ordinances, rules and regulations applicable to them for the ownership, testing, development, manufacture, packaging, processing,
use, labeling, storage, or disposal of any product manufactured by or on behalf of the Company or its Subsidiaries or out-licensed
by the Company or its Subsidiaries (a “Company Product”), including without limitation, the Federal Food, Drug, and
Cosmetic Act, 21 U.S.C. § 301, et seq., the Public Health Service Act, 42 U.S.C. § 262, similar laws of other governmental
entities and the regulations promulgated pursuant to such laws (collectively, “Applicable Laws”); (ii) the Company
and its Subsidiaries possess all material licenses, certificates, approvals, authorizations, permits and supplements or amendments
thereto required by any such Applicable Laws and/or for the ownership of their respective properties or the conduct of their respective
businesses as it relates to a Company Product and as described in the SEC Filings (collectively, “Authorizations”)
and such Authorizations are valid and in full force and effect and the Company and its Subsidiaries are not in violation of any
material term of any such Authorizations; (iii) neither the Company nor any of its Subsidiaries have received any written notice
of adverse finding, warning letter or other written correspondence or notice from the U.S. Food and Drug Administration (the “FDA”)
or any other governmental entity alleging or asserting noncompliance with any Applicable Laws or Authorizations relating to a Company
Product; (iv) neither the Company nor its Subsidiaries have received written notice of any ongoing claim, action, suit, proceeding,
hearing, enforcement, investigation, arbitration or other action from any governmental entity or third party alleging that any
Company Product, operation or activity related to a Company Product is in violation of any Applicable Laws or Authorizations or
has any Knowledge that any such governmental entity or third party is considering any such claim, litigation, arbitration, action,
suit, investigation or proceeding, nor, to the Company’s Knowledge, has there been any noncompliance with or violation of
any Applicable Laws by the Company or any of its Subsidiaries that would reasonably be expected to require the issuance of any
such written notice or result in an investigation, corrective action, or enforcement action by the FDA or similar governmental
entity with respect to a Company Product; (v) neither the Company nor any of its Subsidiaries have received written notice that
any governmental entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations or
has any Knowledge that any such governmental entity has threatened or is considering such action with respect to a Company Product;
and (vi) the Company and each of its Subsidiaries have filed, obtained, maintained or submitted all material reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or
Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements
or amendments were complete correct in all material respects and not misleading on the date filed (or were corrected or supplemented
by a subsequent submission). To the Company’s Knowledge, neither the Company nor any of its Subsidiaries nor any of their
respective directors, officers, employees or agents, has made, or caused the making of, any false statements on, or material omissions
from, any other records or documentation prepared or maintained to comply with the requirements of the FDA or any other governmental
entity.

 

    9

     

    

 

4.17         
Compliance in Clinical Trials. The clinical studies and tests conducted by the Company and each of its Subsidiaries
or on behalf of the Company or any of its Subsidiaries, have been and, if still pending, are being conducted in all material respects
pursuant to all Applicable Laws and Authorizations; the descriptions of the results of such clinical studies and tests contained
in the SEC Filings are accurate and complete in all material respects and fairly present the data derived from such clinical studies
and tests; the Company (on a consolidated basis) is not aware of any clinical studies or tests, the results of which the Company
(on a consolidated basis) believes reasonably call into question the research, nonclinical or clinical study or test results described
or referred to in the SEC Filings when viewed in the context in which such results are described; and neither the Company nor any
of its Subsidiaries have received any written notices or correspondence from any governmental entity requiring the termination,
suspension or material modification of any clinical study or test conducted by or on behalf of the Company or any of its Subsidiaries.

 

4.18         
Investment Company. The Company (on a consolidated basis with its Subsidiaries) is not and, after giving effect to
the offering and sale of the Securities, will not be required to register as an “investment company” as defined in
the Investment Company Act of 1940, as amended.

 

4.19         
Governmental Permits, Etc. The Company and each of its Subsidiaries possess all material licenses, certificates,
permits and other authorizations issued by all applicable authorities necessary to conduct their respective businesses, and the
Company and each of its Subsidiaries have not received any written notice of proceedings relating to the revocation or modification
of any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision,
ruling or finding, would have a Material Adverse Effect, whether or not arising from transactions in the ordinary course of business.

 

4.20         
Internal Control over Financial Reporting. The Company (on a consolidated basis) maintains a system of internal accounting
controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general
or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with generally accepted accounting principles and to maintain asset accountability; (iii) access to assets is permitted only in
accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as set
forth below, the Company’s internal controls over financial reporting are effective to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles and the Company is not aware of any material weakness in its internal controls over financial reporting.
The Company maintains “disclosure controls and procedures” (as such term is defined in Rule 13a-15(e) under the Exchange
Act); such disclosure controls and procedures are effective. A material weakness has been identified whereby due to our limited
number of employees, we have not adequately segregated certain duties to ensure that employees are unable to override the internal
control system. During the fiscal year ended June 30, 2020, a Director of Accounting was hired, and additional procedures were
implemented to improve the segregation of duties. However, until additional personnel are hired it is not possible to fully remediate
this material weakness.

 

4.21         
Labor. No labor problem or dispute with the employees of the Company or any of its Subsidiaries exists or, to the
Knowledge of the Company, is threatened.

 

    10

     

    

 

4.22         
ERISA. None of the following events has occurred or exists: (i) a failure to fulfill the obligations, if any, under
the minimum funding standards of Section 302 of the United States Employee Retirement Income Security Act of 1974, as amended (“ERISA”),
and the regulations and published interpretations thereunder with respect to a Plan that is required to be funded, determined without
regard to any waiver of such obligations or extension of any amortization period; (ii) an audit or investigation by the Internal
Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation or any other federal or state governmental
agency or any foreign regulatory agency with respect to the employment or compensation of employees by any of the Company that
could have a Material Adverse Effect; (iii) any breach of any contractual obligation, or any violation of law or applicable qualification
standards, with respect to the employment or compensation of employees by the Company that would reasonably be expected to have
a Material Adverse Effect. None of the following events has occurred or is reasonably likely to occur: (a) a material increase
in the aggregate amount of contributions required to be made to all Plans in the current fiscal year of the Company compared to
the amount of such contributions made in the most recently completed fiscal year of the Company; (b) a material increase in the
 “accumulated post-retirement benefit obligations” (within the meaning of Statement of Financial Accounting Standards
106) of the Company compared to the amount of such obligations in the most recently completed fiscal year of the Company; (c) any
event or condition giving rise to a liability under Title IV of ERISA that could have a Material Adverse Effect; or (d) the filing
of a claim by one or more employees or former employees of the Company related to their employment that could have a Material Adverse
Effect. For purposes of this paragraph, the term “Plan” means a plan (within the meaning of Section 3(3) of ERISA)
subject to Title IV of ERISA with respect to which the Company may have any liability.

 

4.23         
Environmental Laws. The Company and each of its Subsidiaries (i) is in compliance with any and all applicable foreign,
federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous
or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) has received and is in
compliance with all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct its business
and (iii) has not received notice of any actual or potential liability under any environmental law, except where such non-compliance
with Environmental Laws, failure to receive required permits, licenses or other approvals, or liability would not, individually
or in the aggregate, have a Material Adverse Effect, whether or not arising from transactions in the ordinary course of business.
The Company nor any of its Subsidiaries have been named as a “potentially responsible party” under the Comprehensive
Environmental Response, Compensation, and Liability Act of 1980, as amended.

 

4.24         
Foreign Corrupt Practices. The Company (on a consolidated basis) is not nor, to the Knowledge of the Company, any
director, officer, agent, or employee of the Company or any of its Subsidiaries is aware of or has taken any action, directly or
indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the
rules and regulations thereunder (the “FCPA”), including, without limitation, making use of the mails or any
means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization
of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any
 “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any
candidate for foreign political office, in contravention of the FCPA.

 

4.25         
Money Laundering Laws. The operations of the Company and each of its Subsidiaries are and have been conducted at
all times in compliance with applicable financial recordkeeping and reporting requirements and the money laundering statutes and
the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced
by any governmental agency (collectively, the “Money Laundering Laws”) and no action, suit or proceeding by
or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries
with respect to the Money Laundering Laws is pending or, to the Knowledge of the Company, threatened.

 

    11

     

    

 

4.26         
OFAC. Neither the Company nor any of its Subsidiaries are nor, to the Knowledge of the Company, any director, officer,
agent or employee of the Company or any of its Subsidiaries (i) is currently subject to any sanctions administered or imposed by
the United States (including any administered or enforced by the Office of Foreign Assets Control of the U.S. Treasury Department,
the U.S. Department of State, or the Bureau of Industry and Security of the U.S. Department of Commerce), the United Nations Security
Council, the European Union, or the United Kingdom (including sanctions administered or controlled by Her Majesty’s Treasury)
(collectively, “Sanctions” and such persons, “Sanction Persons”) or (ii) will, directly or
indirectly, use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary,
joint venture partner or other person in any manner that will result in a violation of any economic Sanctions by, or could result
in the imposition of Sanctions against, any person (including any person participating in the offering, whether as underwriter,
advisor, investor or otherwise). Neither the Company nor any of its Subsidiaries is nor, to the Knowledge of the Company, any director,
officer, agent, or employee of the Company or any of its Subsidiaries, is a person that is, or is 50% or more owned or otherwise
controlled by a person that is: (a) the subject of any Sanctions; or (b) located, organized or resident in a country or territory
that is, or whose government is, the subject of Sanctions that broadly prohibit dealings with that country or territory (currently,
Cuba, Iran, North Korea, Sudan, and Syria) (collectively, “Sanctioned Countries” and each, a “Sanctioned
Country”). The Company nor any of its Subsidiaries have engaged in any dealings or transactions with or for the benefit
of a Sanctioned Person, or with or in a Sanctioned Country, in the preceding 3 years, nor does the Company (on a consolidated basis)
have any plans to increase its dealings or transactions with Sanctioned Persons, or with or in Sanctioned Countries.

 

4.27         
Nasdaq Listing Requirements and Uplisting. As of the date hereof, the Company meets, or will meet upon the filing
of its Annual Report on Form 10-K for the fiscal year ended June 30, 2020 and updating its definitive listing application as set
forth in Section 7 hereof (the “Definitive Listing Application”), without regard to the proceeds of the
offering pursuant to this Agreement, all of the financial and liquidity initial listing criteria of the Nasdaq Capital Market.
With respect to corporate governance requirements for the initial listing on the Nasdaq Capital Market, the Company represents
that it will not seek, if eligible, “controlled company” status under the Nasdaq regulations, and will instead comply
with the full corporate governance requirements applicable to non-controlled companies, subject to applicable phase-in periods.
The Company expects, subject to updating the Definitive Listing Application and the completion of the review and approval process,
to have its Common Stock promptly listed for trading on the Nasdaq Capital Market.

 

4.28         
Reverse Stock Split. The Company has obtained all corporate authorizations and the requisite stockholder approval
to effect the Reverse Stock Split described in Section 7.2, subject only to final approval of the Board of Directors of the specific
ratio within the range approved by the stockholders. The implementation of the Reverse Stock Split is subject only to complying
with applicable securities law regulations regarding its declaration and notice of the record date, and transfer agent logistics.

 

    12

     

    

 

4.29         
No Integrated Offering. Assuming the accuracy of the representations and warranties of the Investors set forth in
Section 5, the Company has not, directly or indirectly through any agent, made any offers or sales of, or solicited any
offers to buy, any Company “security” (as defined in the Securities Act) under circumstances that would adversely
affect reliance by the Company on Section 4(a)(2) for the exemption from registration for the transactions contemplated hereby
or would require registration of any of the Securities under the Securities Act.

 

4.30         
Private Placement. Assuming the accuracy of the representations and warranties of the Investors set forth in Section
5, and in reliance thereon, the offer and sale of the Securities to the Investors as contemplated hereby is exempt from the
registration requirements of the Securities Act.

 

4.31         
Shell Company. The Company is not, and was not within the past three (3) years, an “ineligible issuer”
(as defined in Rule 405 promulgated under the Securities Act).

 

4.32         
Use of Form S-3. Upon the listing of the Common Stock on the Nasdaq Capital Market, the Company meets the registration
and transaction requirements for use of Form S-3 for the registration of the resale of the Shares and the Warrant Shares by the
Investors, subject to the SEC’s guidance and interpretations regarding secondary offerings being considered primary offerings.

 

4.33         
No Stop Order. No stop order or suspension of trading has been imposed as of the date hereof by the OTC Markets Group,
FINRA, the SEC or any other governmental authority or regulatory body with respect to public trading in the Common Stock.

 

4.34         
Sarbanes-Oxley Act. There is and has been no failure on the part of the Company and any of the Company’s directors
or officers (in their capacities as such) to comply with any applicable provision of the Sarbanes-Oxley Act of 2002 and the rules
and regulations promulgated in connection therewith, including, without limitation, Section 402 relating to loans.

 

4.35         
Brokers and Finders. Except for the agreement between the Company and the Placement Agents dated September 15, 2020
and the agreement between the Company and the Advisor dated January 14, 2020, as amended on June 17, 2020, no Person will have,
as a result of the transactions contemplated by the Transaction Documents, any valid right, interest or claim against or upon the
Company, any Subsidiary thereof, the Placement Agents, the Advisor or any Investor for any commission, fee or other compensation
pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company.

 

4.36       
No “Bad Actor” Disqualification. The Company has conducted a factual inquiry including the procurement of relevant
questionnaires from each Covered Person (as defined below) or other means to determine whether any Covered Person is subject to
any of the “bad actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (“Disqualification
Events”). To the Company’s knowledge, after conducting such factual inquiries, no Covered Person is subject to
a Disqualification Event, except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act. The
Company has complied, to the extent applicable, with any disclosure obligations under Rule 506(e) under the Securities Act. “Covered
Persons” are those persons specified in Rule 506(d)(1) under the Securities Act, including the Company; any predecessor
or affiliate of the Company; any director, executive officer, other officer participating in the offering, general partner or
managing member of the Company; any beneficial owner of 20% or more of the Company’s outstanding voting equity securities,
calculated on the basis of voting power; any promoter (as defined in Rule 405 under the Securities Act) connected with the Company
in any capacity at the time of the sale of the Shares; and any person that has been or will be paid (directly or indirectly) remuneration
for solicitation of purchasers in connection with the sale of the Shares (a “Solicitor”), any general partner
or managing member of any Solicitor, and any director, executive officer or other officer participating in the offering of any
Solicitor or general partner or managing member of any Solicitor.

 

    13

     

    

 

5.                 
Representations and Warranties of the Investors. Each Investor hereby severally, and not jointly, represents and
warrants to the Company, the Placement Agents and the Advisor that, as of the date hereof and as of the Closing Date as follows:

 

5.1             
Organization and Existence. Such Investor is a duly organized, validly existing corporation, limited partnership
or limited liability company and in good standing under the Laws of the jurisdiction of its organization.

 

5.2             
Authorization. Such Investor has the requisite corporate (or similar) power and authority and has taken all requisite
action on the part of such Investor, its officers, directors, members and stockholders necessary for (i) the authorization, execution
and delivery of the Transaction Documents to which such Investor is a party and (ii) the authorization of the performance of all
obligations of the Investor hereunder or thereunder. The Transaction Documents to which such Investor is a party constitute the
legal, valid and binding obligations of the Investor, enforceable against such Investor in accordance with their terms, subject
to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium, liquidation and similar Laws of general applicability,
relating to or affecting creditors’ rights generally and to general equitable principles.

 

5.3             
No Conflict, Breach, Violation or Default. The execution, delivery and performance of the Transaction Documents by
such Investor will not (i) conflict with or result in a material breach or material violation of (a) any of the terms and provisions
of, or constitute a material default under, its organizational documents, as in effect as of immediately prior to the Closing,
or (b) any Law or Order of any governmental agency or body or any court, domestic or foreign, in each case having jurisdiction
over such Investor or any of its assets or properties, or (ii) conflict with, or constitute a default (or an event that with notice
or lapse of time or both would become a default) under, result in the creation of any lien, encumbrance or other adverse claim
upon any of the properties or assets of such Investor or give to others any rights of termination, amendment, acceleration or cancellation
(with or without notice, lapse of time or both) of, any material agreement, indenture or instrument to which such Investor is a
party; except in the case of clauses (i)(b) and (ii) such as would not have a material adverse effect on the ability of such Investor
to perform its obligations hereunder.

 

    14

     

    

 

5.4             
Purchase Entirely for Own Account. The Securities to be received by such Investor hereunder, including the Warrant
Shares upon exercise of the Warrants, will be acquired for such Investor’s own account, not as nominee or agent, and not
with a view to the resale or distribution of any part thereof in violation of the Securities Act, and such Investor has no present
agreement, understanding or intention of selling, granting any participation in, or otherwise distributing the same in violation
of the Securities Act without prejudice, subject, however, to such Investor’s right at all times to sell or otherwise dispose
of all or any part of such Securities in compliance with applicable federal and state securities Laws.

 

5.5             
Investment Experience. Such Investor acknowledges that it can bear the economic risk and complete loss of its investment
in the Securities and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits
and risks of the investment contemplated hereby.

 

5.6             
Disclosure of Information. Such Investor has had an opportunity to review all information related to the Company
requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms
and conditions of the offering of the Securities. Such Investor acknowledges that copies of the SEC Filings have been made available
to it. Such Investor has sought such accounting, legal and tax advice as it has considered necessary to make an informed decision
with respect to its acquisition of the Securities. Such Investor understands that the Placement Agents and the Advisor have acted
solely as the agents of the Company in this placement of the Units and such Investor has not relied on the business or legal advice
of the Placement Agents, the Advisor or any of their agents, counsel or affiliates in making its investment decision hereunder,
and confirms that none of such persons has made any representations or warranties to such Investor in connection with the transactions
contemplated by this Agreement.

 

5.7             
Restricted Securities. Such Investor understands that the Securities are characterized as “restricted securities”
under the U.S. federal securities Laws inasmuch as they are being acquired from the Company in a transaction not involving a public
offering and that under such Laws the Securities may be resold without registration under the Securities Act only in certain limited
circumstances. Such Investor understands that except as provided in the Registration Rights Agreement: (i) the Securities have
not been and are not being registered under the Securities Act or any state securities Laws, and may not be offered for sale, sold,
assigned or transferred unless (a) subsequently registered thereunder, (b) such Investor shall have delivered to the Company an
opinion of counsel, in a form reasonably acceptable to the Company, to the effect that such Securities to be sold, assigned or
transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (c) such Investor provides
the Company with reasonable assurance that such Securities can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A
promulgated under the Securities Act, as amended, (or a successor rule thereto) (collectively, “Rule 144”);
(ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144 and further,
if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or the Person through whom
the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may require compliance with
some other exemption under the Securities Act or the rules and regulations of the SEC thereunder; and (iii) neither the Company
nor any other Person is under any obligation to register the Securities under the Securities Act or any state securities Laws or
to comply with the terms and conditions of any exemption thereunder. Notwithstanding the foregoing, the Securities may be pledged
in connection with a bona fide margin account or other loan or financing arrangement secured by the Securities and such pledge
of Securities shall not be deemed to be a transfer, sale or assignment of the Securities hereunder, and no Investor effecting a
pledge of Securities shall be required to provide the Company with any notice thereof or otherwise make any delivery to the Company
pursuant to this Agreement or any other Transaction Documents.

 

    15

     

    

 

5.8             
Investor Status. At the time such Investor was offered the Securities, it was, and as of the date hereof it is, and
on each date on which it exercises the Warrants it will be, an “accredited investor” as defined in Rule 501(a) under
the Securities Act. Such Investor is not a registered broker-dealer registered under Section 15(a) of the Exchange Act, or a member
of FINRA or an entity engaged in the business of being a broker-dealer. Such Investor is not affiliated with any broker-dealer
registered under Section 15(a) of the Exchange Act, or a member of FINRA or an entity engaged in the business of being a broker-dealer.

 

5.9             
Reliance on Exemptions. Such Investor understands that the Securities are being offered and sold to it in reliance
on specific exemptions from the registration requirements of federal and state securities Laws and that the Company is relying
in part upon the truth and accuracy of, and such Investor’s compliance with, the representations, warranties, agreements,
acknowledgments and understandings of such Investor set forth in the Transaction Documents in order to determine the availability
of such exemptions and the eligibility of such Investor to acquire the Securities.

 

5.10         
No General Solicitation. Such Investor did not learn of the investment in the Securities as a result of any general
solicitation or general advertising.

 

5.11         
Brokers and Finders. Except for the agreement between the Company and the Placement Agents dated September 15, 2020
and the agreement between the Company and the Advisor dated January 14, 2020, as amended on June 17, 2020, no Person will have,
as a result of the transactions contemplated by the Transaction Documents, any valid right, interest or claim against or upon the
Company, any Subsidiary thereof, the Placement Agents and the Advisor or any Investor for any commission, fee or other compensation
pursuant to any agreement, arrangement or understanding entered into by or on behalf of such Investor.

 

5.12         
Prohibited Transactions. Since such time as such Investor was first contacted by the Company or any other Person
acting on behalf of the Company regarding the transactions contemplated hereby, neither such Investor nor any Affiliate of such
Investor which (a) had knowledge of the transactions contemplated hereby, (b) has or shares discretion relating to such Investor’s
investments or trading or information concerning such Investor’s investments, including in respect of the Securities, or
(c) is subject to such Investor’s review or input concerning such Affiliate’s investments or trading has, directly
or indirectly, effected or agreed to effect any short sale, whether or not against the box, established any “put equivalent
position” (as defined in Rule 16a-1(h) under the Exchange Act) with respect to the Common Stock, granted any other right
(including, without limitation, any put or call option) with respect to the Common Stock or with respect to any security that includes,
relates to or derived any significant part of its value from the Common Stock or otherwise sought to hedge its position in the
Shares; provided that nothing in this representation shall apply to Citadel Securities, an affiliate of the Investor that
operates a global market making business.

 

    16

     

    

 

5.13         
Rule 506(d) Representation. Such Investor represents that it is not a person of the type described in Section 506(d)
of Regulation D under the Securities Act that would disqualify the Company from engaging in a transaction pursuant to Section 506
of Regulation D under the Securities Act.

 

5.14         
Bad Actor Disclosure. Such Investor hereby acknowledges and agrees that it has received and reviewed the disclosure
set forth on Annex I attached hereto within a reasonable time prior to the time that such Investor has agreed to purchase the Units.

 

5.15         
Residency. Such Investor is a resident of that jurisdiction specified on such Investor’s signature page hereto.

 

6.                 
Conditions to Closing.

 

6.1             
Conditions to the Investors’ Obligations. The obligation of each Investor to purchase the Shares at the Closing
is subject to the fulfillment to satisfaction, on or prior to the Closing Date, of the following conditions, any of which may be
waived by such Investor (as to itself only):

 

(a)              
The representations and warranties made by the Company in Section 4 hereof shall be true and correct in all
material respects (except for those representations and warranties that are qualified by materiality or Material Adverse Effect,
which shall be true and correct in all respects) as of the Closing Date, except to the extent any such representation or warranty
expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material
respects (except for those representations and warranties that are qualified by materiality or Material Adverse Effect, which shall
be true and correct in all respects) as of such earlier date. The Company shall have performed in all material respects all obligations
and covenants herein required to be performed by it on or prior to the Closing Date.

 

(b)              
The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing Date.

 

(c)              
a Certificate of the Secretary of the Company, dated as of the Closing Date, shall be delivered (i) certifying the
resolutions adopted by the Board of Directors of the Company and any duly authorized committee thereof relating to the transactions
contemplated by this Agreement and the other Transaction Documents and the issuance of the Securities, (ii) certifying the
current versions of the certificate of incorporation, as amended, and bylaws of the Company and (iii) certifying as to the signatures
and authority of persons signing the Transaction Documents and related documents on behalf of the Company, in form and substance
reasonably acceptable to the Investors (the “Secretary’s Certificate”);

 

(d)              
No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any
bankruptcy court or judge, in each case having authority over the Company or its Subsidiaries, or any order of or by any applicable
governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority,
enjoining or preventing the consummation of the transactions contemplated hereby or in the other Transaction Documents.

 

    17

     

    

 

(e)              
The Company shall have delivered a Certificate, executed on behalf of the Company by its Chief Executive Officer or its
Chief Financial Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in subsections
(a) and (b), of this Section 6.1.

 

(f)               
The Investors shall have received an opinion of (i) Company Counsel dated as of the Closing Date and (ii) Company Intellectual
Property Counsel, each in a form and substance reasonably acceptable to the Investors, addressed to the Investors, the Placement
Agents and the Advisor.

 

(g)              
The Company shall have executed and delivered the Transaction Documents to each Investor.

 

(h)              
No stop order or suspension of trading shall have been imposed or threatened in writing by the OTC Markets Group, FINRA,
the SEC or any other governmental or regulatory body with respect to public trading in the Common Stock.

 

(i)                
The Company shall not have entered into any other Securities Purchase Agreement with a lower purchase price per Unit or
other terms (economic or otherwise) more favorable to such other subscriber or investor than as set forth in this Securities Purchase
Agreement.

 

6.2             
Conditions to the Company’s Obligations. The Company’s obligation to sell and issue the Shares at the
Closing to each Investor is subject to the fulfillment on or prior to the Closing Date of the following conditions, any of which
may be waived by the Company:

 

(a)              
The representations and warranties made by such Investor in Section 5 hereof shall be true and correct in all material
respects (except for those representations and warranties that are qualified by materiality or Material Adverse Effect, which shall
be true and correct in all respects) as of the date hereof as of the Closing Date, except to the extent any such representation
or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in
all material respects (except for those representations and warranties that are qualified by materiality or Material Adverse Effect,
which shall be true and correct in all respects) as of such earlier date. Each Investor shall have performed in all material respects
all obligations and covenants herein required to be performed by it on or prior to the Closing Date.

 

(b)              
Each Investor shall have delivered its applicable portion of the Purchase Price to the Company.

 

(c)              
Each Investor shall have executed and delivered the Transaction Documents to the Company.

 

    18

     

    

 

6.3             
Termination of Obligations to Effect Closing; Effects.

 

(a)              
The obligations of the Company, on the one hand, and the Investors, on the other hand, to effect the Closing shall terminate
as follows:

 

(i)                
Upon the mutual written consent of the Company and the Investors;

 

(ii)             
By the Company if any of the conditions set forth in Section 6.2 shall have become incapable of fulfillment,
and shall not have been waived by the Company;

 

(iii)           
By an Investor (with respect to itself only) if any of the conditions set forth in Section 6.1 shall have become
incapable of fulfillment, and shall not have been waived by such Investor; or

 

(iv)            
By either the Company or any Investor (with respect to itself only) if the Closing has not occurred prior to 11:59 PM (New
York time) on October 23, 2020;

 

provided, however, that, except in the
case of clause (i) above, the party seeking to terminate its obligation to effect the Closing shall not then be in breach
of any of its representations, warranties, covenants or agreements contained in this Agreement or the other Transaction Documents
if such breach has resulted in the circumstances giving rise to such party’s seeking to terminate its obligation to effect
the Closing.

 

(b)              
In the event of termination by the Company or any Investor of its obligations to effect the Closing pursuant to this Section 6.3,
written notice thereof shall forthwith be given to the other Investors by the Company and the other Investors shall have the right
to terminate their obligations to effect the Closing upon written notice to the Company and the other Investors. Nothing in this
Section 6.3 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions
of this Agreement or the other Transaction Documents or to impair the right of any party to compel specific performance by any
other party of its obligations under this Agreement or the other Transaction Documents.

 

7.                 
Other Covenants and Agreements of the Parties.

 

7.1             
Reverse Stock Split. The Board of Directors shall declare a reverse stock split of the Company’s issued and
outstanding Common Stock at a ratio ranging between 1-to-20 and 1-to-100, and to be effective upon a date on or prior to October
23, 2020, such ratio and date to be determined by the Board of Directors, as described in the Company’s definitive proxy
statement filed with SEC on September 23, 2019 and as approved by the Company’s stockholders at a special meeting of stockholders
held on October 23, 2019 (the “Reverse Stock Split”).

 

7.2             
Form NT 10-K. The Company shall timely file, pursuant to Rule 12b-25 under the Exchange Act, its Annual Form Report
on Form 10-K for the fiscal years ended June 30, 2020 by no later than October 13, 2020, and such filing shall comply with all
the applicable disclosure requirements thereof, including the requisite audited financial statements and audit report thereof by
the Company’s independent registered public accounting firm.

 

    19

     

    

 

7.3             
Nasdaq Capital Market Listing. The Company shall (a) update its filing of the Definitive Listing Application of its
Common Stock with the Nasdaq Capital Market no later than October 13, 2020, and use its best efforts to complete the listing process
and secure the trading of the Common Stock on the Nasdaq Capital Market as promptly as possible; (b) comply with the full corporate
governance requirements applicable to non-controlled companies, subject to applicable phase-in periods and (c) promptly secure
and maintain the listing of all of the Registrable Securities (as defined in the Registration Rights Agreement) pursuant to the
terms set forth in the Registration Rights Agreement.

 

7.4             
Preemptive Rights of Lead Investor. During the Preemptive Period, in all future primary offerings by the Company,
the Lead Investor shall have the right to participate on a pro rata basis on the same terms and conditions as the offerees, as
described below. In furtherance of this right, the Company agrees to provide notice to the Lead Investor of such offerings. The
Lead Investor will be deemed to have declined the right to participate in such offerings if: (i) the Company or its underwriter,
placement agent or financial advisor in good faith attempts to inform the Lead Investor of such offering on a confidential basis
pursuant to a customary “wall crossing” procedure and the Lead Investor declines to speak with the Company or its underwriter,
placement agent or financial advisor regarding the offering (i.e., it does not come “over the wall”) (it being understood
that the Lead Investor will be deemed to have “declined to speak” to the Company or its underwriter, placement agent
or financial advisor, and thus have declined the right to participate in such offering, if it could not be reached or does not
provide a response within 48 hours after such good faith attempt to inform the Lead Investor of such offering); or (ii) the Company
or its underwriter, placement agent or financial advisor contacts the Lead Investor following the first public announcement of
the public offering and the Lead Investor is offered an allocation of or is allocated in such offering the lesser of: (A) its requested
allocation in such public offering or (B) its Qualified Percentage Interest; or (iii) if the Lead Investor cannot be found or is
not responsive during the period between the first public announcement of the public offering and the pricing of such public offering
(which may be the same day as the announcement in the case of a confidentially marketed public offering). Notwithstanding anything
to the contrary herein, this Section 7.4 shall not (1) apply to any offering or sale of securities on Form S-8 or Form S-4,
or any similar or successor forms, (2) apply to the filing or effectiveness of any shelf registration statement, whether covering
potential sales of Company securities by the Company or resales of Company securities by selling security holders, (3) apply to
offers or sales under any resale registration statement by security holders of the Company, (4) apply to any offering or sale pursuant
to an “at the market” offering by the Company, or (5) require the Company to take any action that would require shareholder
approval under applicable stock exchange rules or result in a violation of law or stock exchange rule or regulation.  Notwithstanding
anything herein to the contrary, this Section 7.4 may be waived by a written instrument signed by the Lead Investor.

 

7.5             
Legends. The Securities shall bear the following legends:

 

(a)              
“The securities represented hereby have not been registered with the Securities and Exchange Commission or the securities
commission of any state in reliance upon an exemption from registration under the Securities Act of 1933, as amended, and, accordingly,
may not be transferred unless (i) such securities have been registered for sale pursuant to the Securities Act of 1933, as amended,
(ii) such securities may be sold pursuant to Rule 144, or (iii) the Company has received an opinion of counsel reasonably satisfactory
to it that such transfer may lawfully be made without registration under the Securities Act of 1933, as amended.” Notwithstanding
the foregoing, the securities may be pledged in connection with a bona fide margin account or other loan or financing arrangement
secured by the securities.

 

    20

     

    

 

(b)              
If required by the authorities of any state in connection with the issuance of sale of the Securities, the legend required
by such state authority.

 

7.6             
Removal of Legends.

 

(a)              
In connection with any sale, assignment, transfer or other disposition of the Securities by an Investor pursuant to Rule
144 or pursuant to any other exemption under the Securities Act such that the purchaser acquires freely tradable securities and
upon compliance by such Investor with the requirements of this Agreement, if requested by such Investor, the Company shall cause
the Transfer Agent to timely remove any restrictive legends related to the book entry account holding such Securities and make
a new, unlegended entry for such book entry Securities sold or disposed of without restrictive legends, provided that the Company
has received from the Investor customary representations and other documentation reasonably acceptable to the Company in connection
therewith.

 

(b)              
Upon the earliest of (i) the Securities being subject to an effective registration statement covering the resale of the
Securities, (ii) such time as the Securities have been sold pursuant to Rule 144, or (iii) such time as the Securities are eligible
for resale under Rule 144(b)(1) or any successor provision, the Company shall, no later than Two Business Days thereafter, (A)
deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such book
entry Securities, together with (solely in the case of an “unlegending” in connection with a sale pursuant to Rule
144 as contemplated by subclause (ii)), a customary representation by the Investor that Rule 144 applies to the Securities represented
thereby and (B) cause its counsel to deliver to the Transfer Agent one or more opinions to the effect that the removal of such
legends in such circumstances may be effected under the Securities Act if required by the Transfer Agent to effect the removal
of the legend in accordance with the provisions of this Agreement. The Company agrees that following such time as such legend is
no longer required under this Section 7.4, it will, upon an Investor’s written request and compliance with the immediately
preceding sentence, deliver or cause to be delivered to such Investor, a certificate representing that such Securities are free
from all restrictive and other legends. Securities subject to legend removal hereunder shall be transmitted by the Transfer Agent
to the Investor by crediting the account of the Investor’s custodian as directed by such Investor.

 

7.7             
Furnishing of Information. In order to enable the Investors to sell the Securities under Rule 144, until the date
that the Shares and the Warrant Shares cease to be Registrable Securities (as defined in the Registration Rights Agreement), the
Company shall use its commercially reasonable efforts to timely file (or obtain extensions in respect thereof and file within the
applicable grace period) all reports required to be filed by the Company after the Effective Date pursuant to the Exchange Act.
During such period, if the Company is not required to file reports pursuant to the Exchange Act, it will prepare and furnish to
the Investors and make publicly available in accordance with Rule 144(c) such information as is required for the Investors to sell
the Securities under Rule 144.

 

    21

     

    

 

7.8             
Indemnification of Investors. Subject to the provisions of this Section 7.8, the Company will indemnify
and hold each Investor, its officers, directors, agents, partners, members, managers, stockholders, affiliates, employees and investment
advisors, and each person who controls such Investor (within the meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act), and the officers, directors, partners, members, managers, stockholders, agents, affiliates, employees and investment
advisers of each such controlling person, to the fullest extent permitted by applicable Law, harmless from any and all losses,
liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements,
court costs and reasonable attorneys’ fees and costs of investigation, as incurred, that arise out of or are based upon (i)
any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement, or (ii) any
violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law or any rule or
regulation thereunder, in connection with the performance of its obligations under this Section 7, except to the extent,
but only to the extent, that such untrue statements, alleged untrue statements, omissions or alleged omissions are based upon information
regarding the undersigned furnished in writing to the Company by the Investor expressly for use therein. The Company shall notify
the Investor promptly of the institution, threat or assertion of any proceeding arising from or in connection with the transactions
contemplated by this Section 7 of which the Company is aware. Such indemnity shall remain in full force and effect regardless
of any investigation made by or on behalf of an indemnified party and shall survive the transfer of Units (or the underlying Common
Stock or Warrants) by the Investor. Notwithstanding the forgoing, the Company’s indemnification obligations shall not apply
to amounts paid in settlement of any losses or action if such settlement is effected without the prior written consent of the Company
(which consent shall not be unreasonably withheld or delayed); provided, however, that the aggregate liability of
the Company to each Investor under this Section 7.8 shall not exceed the amount paid by such Investor to the Company pursuant
to Section 3. Promptly after receipt by any Investor (the “Indemnified Person”)
of notice of any demand or claim from any Person that would or might give rise to a claim or the commencement of any action, proceeding
or investigation in respect of which indemnification may be sought pursuant to this Section 7.8 (a “Third Party
Claim”), such Indemnified Person shall promptly notify the Company in writing, and in reasonable detail, of such Third
Party Claim. Thereafter, the Indemnified Person will deliver to the Company, within five (5) Business Days after the Indemnified
Person’s receipt thereof, copies of all notices and documents (including court papers) received by the Indemnified Person
relating to the Third Party Claim. If a Third Party Claim is made against the Company, the Company will be entitled to participate
in the defense thereof and, if it so chooses, to assume the defense thereof (subject to a reservation of rights) with counsel selected
by the Company by giving the Indemnified Person notice within twenty (20) days of the Company’s receipt of notice of the
Third Party Claim pursuant to this Section 7.8. If the Company does not give such notice to the Indemnified Person
of the Company’s intent to assume the defense of the Third Party Claim, the Indemnified Person shall be entitled to assume
the defense thereof. Should the Company so elect to assume the defense of a Third Party Claim, the Company will not be liable to
the Indemnified Person for legal expenses subsequently incurred by the Indemnified Person in connection with the defense thereof.
If the Company assumes such defense, the Indemnified Person will have the right to participate in the defense thereof and to employ
counsel, at its own expense, separate from the counsel employed by the Company, it being understood, however, that the Company
will control such defense. If the Company chooses to defend any Third Party Claim, then all the Parties will cooperate in the defense
or prosecution of such Third Party Claim. The Indemnified Person will not admit any liability with respect to, or settle, compromise
or discharge, any Third Party Claim without the prior written consent of the Company. Notwithstanding any other provision of this
Agreement, the Company shall not enter into settlement of any Third Party Claim without the prior written consent of the Indemnified
Person (which consent shall not be unreasonably withheld), unless such settlement requires only the payment of money that the Company
is obligated to pay.

 

    22

     

    

 

7.9             
Equal Treatment of Investors. No consideration shall be offered or paid to any Person to amend or consent to a waiver
or modification of any provision of any of the Transaction Documents unless the same consideration is also offered to all of the
Parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Investor
by the Company and negotiated separately by each Investor, and is intended for the Company to treat the Investors as a class and
shall not in any way be construed as the Investors acting in concert or as a group with respect to the purchase, disposition or
voting of Securities or otherwise.

 

7.10         
Compliance with Laws. Notwithstanding any other provision of this Agreement, each Investor covenants that
the Securities may be disposed of only pursuant to an effective registration statement under, and in compliance with the requirements
of, the Securities Act, or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements
of the Securities Act, and in compliance with any applicable state and federal securities Laws. In connection with any transfer
of the Securities other than (i) pursuant to an effective registration statement, (ii) to the Company, (iii) pursuant to Rule 144
(provided that the Investor provides the Company with reasonable assurances (in the form of seller and, if applicable, broker representation
letters) that the Securities may be sold pursuant to such rule), or (iv) to its Affiliates, the Company may require the transferor
thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the
form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not
require registration of such transferred Securities under the Securities Act. As a condition of transfer, any such transferee shall
agree in writing to be bound by the terms of this Agreement and shall have the rights of an Investor under this Agreement with
respect to such transferred Securities.

 

7.11         
Disclosure
of Material Non-Public Information. The Company shall not disclose material non-public information to the
Investors, or to advisors to or representatives of the Investors, unless prior to disclosure of such information the Company identifies
such information as being material non-public information and provides the Investors, such advisors and representatives
with the opportunity to accept or refuse to accept such material non-public information for review and any Investor wishing
to obtain such information enters into an appropriate confidentiality agreement with the Company with respect thereto. Except with
respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided any of the Investors or their agents or counsel with any
information that it believes constitutes or might constitute material, non-public information which has been, or will not as of
the Closing be, publicly disclosed. The Company understands and confirms that the Investors will rely on the foregoing representation
in effecting transactions in securities of the Company.

 

    23

     

    

 

7.12        
 Termination
of Certain Obligations. The provisions of Sections 7.3(c) and 7.11 shall terminate and be of no further force
and effect on the date on which the Company’s obligations under the Registration Rights Agreement to register or maintain
the effectiveness of any registration covering the Registrable Securities (as defined in the Registration Rights Agreement) shall
terminate.

 

7.13.        
Reservation
of Common Stock.  The Company shall take all action necessary to at all times during the period the Warrants are
outstanding have authorized, and reserved for the purpose of issuance from and after the Closing Date, the number of shares of
Common Stock issuable upon exercise of the Warrants issued at the Closing.

 

7.14.         CHI Study.
The Company shall commence an epidemiology study to better characterize the prevalence of congenital hyperinsulinism (“CHI”)
and will use its best efforts to promptly complete such study.

 

7.15.          Subsequent Equity
Sales. From the date hereof until sixty (60) days after the Effective Date, neither the Company nor any Subsidiary shall issue,
enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock equivalents.
Notwithstanding the foregoing, this Section shall not apply with respect to an Exempt Issuance, and may be waived by the prior
written consent of the Required Investors (as defined in the Registration Rights Agreement).

 

7.16.          Reporting Status.
the Company shall not terminate its status as an issuer required to file reports under the Exchange Act unless the Exchange Act
or the rules and regulations thereunder would no longer require or otherwise permit such termination, and the Company shall take
all actions reasonably necessary to maintain its eligibility to register the Shares for resale by the Investors on Form S-3 or,
if it is ineligible to use Form S-3, on Form S-1.

 

8.             
Survival. The representations, warranties, covenants and agreements contained in this Agreement shall survive for
a period of one (1) year following the Closing.

 

9.            
Miscellaneous.

 

9.1             
Assignment. This Agreement may not be assigned by a party hereto without the prior written consent of the Company
or the Investors, as applicable.

 

9.2             
Successors. This Agreement shall be binding solely on, and inure solely to the benefit of, each of the undersigned
and their respective successors and permitted assigns, and nothing set forth in this Agreement shall be construed to confer upon
or give to any Person other than each of the undersigned and their respective successors and permitted assigns any benefits, rights
or remedies under or by reason of, or any rights to enforce or cause the Company to enforce, the equity commitment or any provisions
of this Agreement. Notwithstanding the foregoing, the Company and the Investors acknowledge and agree that the Placement Agents
and the Advisor are intended third party beneficiaries of Section 4 and Section 5 hereof and that the Placement Agents and the
Advisor may enforce the provisions of such Sections directly against the parties with obligations thereunder.

 

    24

     

    

 

9.3             
Counterparts; Faxes; Electronic Mail. This Agreement may be executed in two or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may also be executed
via facsimile or electronic mail, each of which shall be deemed an original.

 

9.4             
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to
be considered in construing or interpreting this Agreement.

 

9.5             
Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing
and shall be deemed effectively given as hereinafter described: (i) if given by personal delivery, then such notice shall be deemed
given upon such delivery; (ii) if given by facsimile, then such notice shall be deemed given upon receipt of confirmation of complete
transmittal; (iii) if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such notice by the
recipient or (B) three (3) days after such notice is deposited in first class mail, postage prepaid; and (iv) if given by an internationally
recognized overnight air courier, then such notice shall be deemed given one (1) Business Day after delivery to such carrier. All
notices shall be addressed to the party to be notified at the address as follows, or at such other address as such party may designate
by ten (10) days’ advance written notice to the other party:

 

If to the Company:

Rezolute, Inc.

201 Redwood Shores Pkwy, Suite 315

Redwood City, CA 94065

Attn: Nevan Elam, CEO

 

With a copy to:

Dorsey & Whitney LLP,

1400 Wewatta Street, Suite 400

Denver, CO 80202-5549

Attn:      Anthony W. Epps, Esq.

If to the Investors:

to the addresses set forth on the signature pages hereto.

 

9.6             
Expenses. The Parties shall pay their own costs and expenses in connection herewith; provided, however,
following the Closing, the Company shall pay the reasonable fees and expenses of the Lead Investor, including its reasonable attorney’s
fees and costs, up to a maximum aggregate amount of $65,000. In the event that legal proceedings are commenced by any party to
this Agreement against another party to this Agreement in connection with any Transaction Document, the party or parties to such
proceeding which do not prevail in such proceedings shall severally, but not jointly, pay their pro rata share of the reasonable
attorneys’ fees and other reasonable out-of-pocket costs and expenses incurred by the prevailing party in such proceedings.

 

    25

     

    

 

9.7             
Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement
may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent
of the Company and the Required Investors. Any amendment or waiver effected in accordance with this paragraph shall be binding
upon each holder of any Securities purchased under this Agreement at the time outstanding, each future holder of all such Securities,
and the Company.

 

9.8             
Publicity. Except as set forth below, no public release or announcement concerning the transactions contemplated
hereby shall be issued by the Company or the Investors without the prior written consent of the Company (in the case of a release
or announcement by the Investors) or the Required Investors (in the case of a release or announcement by the Company) (which consents
shall not be unreasonably withheld), except (i) as such release or announcement may be required by Law or the applicable rules
or regulations of the SEC, any securities exchange or securities market, in which case the Company or the Investors, as the case
may be, shall allow the Investors or the Company, as applicable, to the extent reasonably practicable in the circumstances, reasonable
time to comment on such release or announcement in advance of such issuance or (ii) a public release or announcement in connection
with discussions to investors not including the Required Investors, in which case such consent shall not be required. Notwithstanding
the foregoing, no Investor may be named in a public release or announcement concerning the transactions contemplated hereby without
such Investor’s prior written consent. The Investors hereby acknowledge and agree that no later than the Business Day immediately
following the Effective Date, the Company shall (x) issue a press release reasonably acceptable to the Required Investors and (y)
file a Current Report on Form 8-K describing the terms of the transactions contemplated by the Transaction Documents in the form
required by the Exchange Act and attaching the material Transaction Documents (including, without limitation, this Agreement (and
all schedules and exhibits to this Agreement but not the signature pages hereto), the form of Warrant and the Registration Rights
Agreement, as exhibits to such filing (including all attachments)). In addition, the Company will make such other filings and notices
in the manner and time required by the SEC or the Nasdaq Capital Market, the Warrants and the Registration Rights Agreement. From
and after the issuance of such press release and the filing of the Current Report on Form 8-K, the Company represents to the Investors
that, as of the Closing, it shall have publicly disclosed all material, non-public information delivered to any of the Investors
by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection with
the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the
Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or
oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates
on the one hand, and any of the Investors or any of their Affiliates on the other hand, shall terminate.

 

    26

     

    

 

9.9             
Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to
such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions
hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable Law,
and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in
any other jurisdiction. To the extent permitted by applicable Law, the Parties hereby waive any provision of Law which renders
any provision hereof prohibited or unenforceable in any respect.

 

9.10         
Entire Agreement. This Agreement, including the Exhibits, the Warrants and the Registration Rights Agreement constitute
the entire agreement among the Parties with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, both oral and written, among the Parties with respect to the subject matter hereof and thereof.

 

9.11         
Further Assurances. The Parties shall execute and deliver all such further instruments and documents and take all
such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment
of the agreements herein contained.

 

9.12         
Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed
in accordance with, the internal Laws of the State of Delaware without regard to the choice of law principles thereof. Each of
the Parties irrevocably submits to the exclusive jurisdiction of the courts of the Delaware Court of Chancery and any state appellate
court therefrom within the State of Delaware Court of Chancery and any state appellate court therefrom within the State of Delaware
(or, if the Delaware Court of Chancery declines to accept jurisdiction over a particular mater, any state or federal court within
the State of Delaware) for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement
and the transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding may be served
on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement.
Each of the Parties irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the
laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action
or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such
court has been brought in an inconvenient forum. EACH OF THE PARTIES WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION
WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

9.13         
Disclaimer. Except as expressly set forth in this Agreement, no Party makes any representation or warranty to any
other Party of any nature, express or implied. Each Investor acknowledges and agrees that in evaluating its investment in the Securities,
it is not relying on any representations, warranties or information (including the accuracy or completeness thereof) other than
the representations and warranties contained herein and the information contained in the SEC Filings.

 

9.14         
Independent Nature of Investors’ Obligations and Rights. The obligations of each Investor under any Transaction
Document are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way
for the performance of the obligations of any other Investor under any Transaction Document. The decision of each Investor to purchase
Securities pursuant to the Transaction Documents has been made by such Investor independently of any other Investor. Nothing contained
in any Transaction Document, and no action taken by any Investor pursuant thereto, shall be deemed to constitute the Investors
as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in
any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents.
Each Investor acknowledges that no other Investor has acted as agent for such Investor in connection with making its investment
hereunder and that no Investor will be acting as agent of such Investor in connection with monitoring its investment in the Securities
or enforcing its rights under the Transaction Documents. Each Investor shall be entitled to independently protect and enforce its
rights, including, without limitation, the rights arising out of the Transaction Documents, and it shall not be necessary for any
other Investor to be joined as an additional party in any proceeding for such purpose. The Company acknowledges that each of the
Investors has been provided with the same Transaction Documents for the purpose of closing a transaction with multiple Investors
and not because it was required or requested to do so by any Investor.

 

[Signature pages follow]

 

    27

     

    

 

IN WITNESS WHEREOF,
the Parties have executed this Agreement as of the date first indicated above.

 

	The
Company:	REZOLUTE, INC.
	 	 
	 	By:	/s/ Keith Vendola
	 	Name:
    Keith Vendola
	 	Its:
    Chief Financial Officer

 

[Signature Page
to PIPE – Securities Purchase Agreement]

 

     

     

    

 

IN WITNESS WHEREOF,
the Parties have executed this Agreement as of the date first indicated above.

 

	 	
	 	 
	 	By:	 
	 	Name: 	                                    	 
	 	Its: 	 	 
	 	Aggregate
Purchase Price (Subscription Amount): $
	 	 
	 	Number
    of Shares to be Acquired:____________
	 	 
	 	Underlying
    Shares Subject to Warrant: _________
	 	(33%
    of the number of Shares to be acquired)
	 	 
	 	Tax
    ID No.: ____________________
	 	 
	 	Address
    for Notice/Residency of Investor:
	 	 
	 	 
	 	 
	 	 
	 	 
	 	Telephone
    No.: _______________________
	 	 
	 	Facsimile
    No.: ________________________
	 	 
	 	E-mail
    Address: ________________________
	 	Attention:
    _______________________

 

Delivery Instructions:

(if different than above)

c/o _______________________________

Street: ____________________________

City/State/Zip: ______________________

Attention: __________________________

Telephone No.: ____________________________

 

[Signature Page
to PIPE – Securities Purchase Agreement]

 

     

     

    

 

ANNEX I

 

Regulation D Rule 506 Disclosure

 

On March 24, 2016, the Securities and Exchange
Commission (“SEC”) Division of Corporation Finance, pursuant to delegated authority, granted a waiver to Canaccord
Genuity Inc. (“Canaccord”) from the bad actor provisions of Rule 506(d) of Regulation D and Rule 262 of Regulation
A under the Securities Act of 1933 (“Securities Act”) that would otherwise apply to Canaccord due to an SEC
administrative order issued on the same day. In the administrative order, Canaccord, without admitting or denying any allegations,
was ordered to cease and desist from violations of Section 5 of the Securities Act based on the initiation of research coverage
for an issuer after Canaccord had been invited by the issuer to participate as an underwriter for a secondary stock offering that
was planned for at least one month later. Canaccord also was ordered to pay $407,481 in disgorgement, $42,717 in prejudgment interest
and $100,000 in civil money penalties.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]